+ All Categories

Home > Documents > Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Date post:	31-Dec-2015
Category:	Documents
Upload:	zachary-rivas
View:	31 times
Download:	0 times

Download Report this document

Share this document with a friend

Description:

Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer. Program Goals. - PowerPoint PPT Presentation

Embed Size (px):

32

Radiopharmaceuticals in Metastatic Castration- Resistant Prostate Cancer

Transcript

Page 1: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Rationale for Radiopharmaceuticals in

Metastatic Castration-Resistant Prostate Cancer

Page 2: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Program Goals

Page 3: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 4: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 5: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 6: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 7: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 8: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 9: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 10: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 11: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 12: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 13: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 14: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 15: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 16: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 17: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 18: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 19: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 20: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 21: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 22: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 23: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 24: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 25: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 26: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 27: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 28: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 29: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 30: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 31: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Page 32: Rationale for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer

Recommended

Defining Personalized Care Plans in Metastatic Castration-Resistant Prostate Cancer

Metastatic castration-resistant prostate cancer reveals ... · identify new actionable targets in CRPC is crucial as we begin to ... but rather pathway activationwithin thetumorsthemselves.

Metastatic castration resistant prostate cancer: Current ... · castration resistant prostate cancer: Current strategies of management ... Recent advances have also led to an unprecedented

richtlijnendatabase.nl · Web viewAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall analysis of the COU-AA-301 randomised, double-blind,

Metastatic castration resistant prostate cancer (mCRPC) · Prostate Cancer: Castration resistant (CRPC) ADT: Androgen Deprivation Therapy M0: By imaging no evidence of metastases

The Role of AR-V7 in the Management of Metastatic ... · The Role of AR-V7 in the Management of Metastatic Castration -Resistant Prostate Cancer Deborah Davison, DNP Associate Director,

Metastatic castration-resistant prostate cancer reveals intrapatient

Consultant Medical Oncologist Mahatma Gandhi Cancer ... · Metastatic castration sensitive prostate cancer Dr B. RakeshReddy MD DM ECMO Consultant Medical Oncologist Mahatma Gandhi

ESSA NonConfidential Slide Deck March 2019...MARKET VALIDATED THERAPEUTIC TARGET NEED FOR NEW THERAPEUTIC STRATEGIES Metastatic Castration-Resistant Prostate Cancer (mCRPC) 5 An Unmet

Immunotherapy and Bone-Metastatic Castration-Resistant ...appropriately effective modalities for its treatment, especially when it spreads to bone tissue, generating skeletal-related

RL Prostaat - PICO 2 - Methodology report€¦ · Web viewAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of

Role of Surrogate Markers in Management of Men With Metastatic Castration-Resistant Prostate Cancer

Janssen Research & Development, LLC...1 Approved, Date: 19 February 2018 Janssen Research & Development * Clinical Protocol Abiraterone acetate in patients with Metastatic Castration-Resistant

Lutetium-177 PSMA Radioligand Therapy of Metastatic ......2016/01/20 · Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

pan-Canadian Oncology Drug Review Final Clinical …...pan-Canadian Oncology Drug Review Final Clinical Guidance Report Apalutamide (Erleada) for metastatic Castration Sensitive Prostate

A Clinical Trial for - Prostate Health Education Networkprostatehealthed.org/images/11658_MK3475_641_5_5x8... · A Clinical Trial for Metastatic Castration-Resistant Prostate Cancer

pan-Canadian Oncology Drug Review Final Clinical Guidance ... · Metastatic Castration-Resistant Prostate Cancer . June 22, 2015 . pCODR Final Clinical Guidance Report - Enzalutamide

Glucocorticoid Receptor Activity Contributes to Resistance ......metastatic PC is initially treated with castration-based thera-pies to eliminate testicular androgen production [18].